Literature DB >> 9817300

Advanced testicular cancer: update for urologists.

L H Einhorn1, J P Donohue.   

Abstract

PURPOSE: Testicular cancer is a model for a curable neoplasm. We review past and present accomplishments in treating testis cancer and emphasize controversial surgical issues of interest to the urologist.
MATERIALS AND METHODS: We reviewed early and recent chemotherapy trials of germ cell tumors, stressing random prospective phase III studies. In addition, we address specific and complicated issues that are of particular relevance for the urologist, analyzing recently published articles.
RESULTS: Cisplatin combination chemotherapy has dramatically improved the cure rate for patients with germ cell tumors. The indications for post-chemotherapy resection for residual masses are discussed.
CONCLUSIONS: The major goal 25 years ago was to develop a successful chemotherapy regimen for disseminated disease, which has now been accomplished with cisplatin combination chemotherapy. Present issues include optimal treatment in patients with poor prognostic characteristics, salvage chemotherapy strategies and indications for post-chemotherapy surgical resection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9817300

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  3 in total

Review 1.  Therapeutic vaccination with tumor cells that engage CD137.

Authors:  Karl Erik Hellstrom; Ingegerd Hellstrom
Journal:  J Mol Med (Berl)       Date:  2003-02-08       Impact factor: 4.599

2.  Cisplatin-induced alterations in the functional spermatogonial stem cell pool and niche in C57/BL/6J mice following a clinically relevant multi-cycle exposure.

Authors:  James G Harman; John H Richburg
Journal:  Toxicol Lett       Date:  2014-04-02       Impact factor: 4.372

3.  Laparoscopic and open postchemotherapy retroperitoneal lymph node dissection in patients with advanced testicular cancer--a single center analysis.

Authors:  Jonas Busch; Ahmed Magheli; Barbara Erber; Frank Friedersdorff; Ivan Hoffmann; Carsten Kempkensteffen; Steffen Weikert; Kurt Miller; Mark Schrader; Stefan Hinz
Journal:  BMC Urol       Date:  2012-05-31       Impact factor: 2.264

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.